<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04483219</url>
  </required_header>
  <id_info>
    <org_study_id>TRAP</org_study_id>
    <nct_id>NCT04483219</nct_id>
  </id_info>
  <brief_title>Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.</brief_title>
  <official_title>A Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Tyrosine Kinase Inhibitor (TKI) in Combination With Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of fruquintinib or&#xD;
      regorafenib in combination with anti-PD-1 antibody in TKI (fruquintinib or&#xD;
      regorafenib)-responded MSS/pMMR metastatic colorectal adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present, the later-line treatment of metastatic colorectal cancer (mCRC) can bring&#xD;
      benefits to subjects. However, the overall efficacy of treatment is still low. The programmed&#xD;
      cell death protein 1 (PD-1) blockade alone in MSS/pMMR mCRC is inefficiency, highlighting a&#xD;
      need for strategies that converse the immunity suppressive to immunity supportive&#xD;
      microenvironment. Fruquintinib and regorafenib are multi-target TKI mainly for angiogenesis,&#xD;
      which has the following characteristics: cause tumor necrosis and release a lot of new&#xD;
      antigens, improve the microenvironment of immunosuppression, and induce tumor vascular&#xD;
      normalization. In addition to killing tumor cells, fruquintinib and regorafenib could also&#xD;
      converse the immunity suppressive to immunity supportive microenvironment, which could&#xD;
      sensitize PD-1 blockade, ultimately improve the prognosis of patients with MSS/pMMR mCRC.&#xD;
&#xD;
      This prospective study is a single-arm, multicenter phase II clinical study to evaluate the&#xD;
      efficacy and safety of fruquintinib or regorafenib in combination with anti-PD-1 antibody in&#xD;
      TKI (fruquintinib or regorafenib)-responded MSS/pMMR metastatic colorectal cancer.&#xD;
&#xD;
      In this prospective study, the 9-month PFS rate in subjects receiving TKI followed by TKI in&#xD;
      combination with anti-PD-1 antibody, will be used as primary outcome measures and 53 subjects&#xD;
      will be recruited.&#xD;
&#xD;
      After fully informed and signed the informed consent, the subjects will receive one cycle of&#xD;
      TKI (fruquintinib or regorafenib) treatment after enrollment. According to response to TKI,&#xD;
      the subjects will be divided into three arms. The definition of response to TKI are as&#xD;
      follows: (1) obvious response to TKI (arm A)：effective imaging changes, including reduction&#xD;
      of target lesion diameter to CR, PR or shrunken SD (based on response evaluation criteria in&#xD;
      solid tumors, RECIST v 1.1), or cavitation in metastatic lung lesions, or decrease in the&#xD;
      density of liver metastatic target lesions ≥15%; (2) general response to TKI (arm B):&#xD;
      enlarged SD (based on RECIST v 1.1); (3) poor response to TKI (arm C): PD (based on RECIST v&#xD;
      1.1). TKI in combination with anti-PD-1 antibody will be administered in arm A. The subjects&#xD;
      in arm C will exit the study. The subjects in arm B will continue to take TKI for another one&#xD;
      cycle. After that, the obvious response subjects will be entered group A, the general&#xD;
      response subjects will keep in arm B and continue the TKI monotherapy, and the poor response&#xD;
      subjects will exit the study. The administration of arm A or B will be last until disease&#xD;
      progression or intolerable toxicity，anti-PD-1 antibody can be applied for up to 2 years.&#xD;
&#xD;
      The first two imaging evaluations would be performed every 4 weeks after the beginning of&#xD;
      treatment to evaluate TKI response, and then once every 6 weeks, until the end of treatment,&#xD;
      withdrawal of informed consent or death. The TKI response would be assessed according to&#xD;
      RECIST v1.1 criteria and effective imaging changes (cavitation in metastatic lung lesions, or&#xD;
      decrease in the density of liver metastatic target lesions ≥15%). The efficacy of TKI&#xD;
      followed by TKI in combination with anti-PD-1 antibody would be evaluated based on&#xD;
      immune-related RECIST (iRECIST) v1.1 criteria.&#xD;
&#xD;
      PD-1/PD-L1 expression, T lymphocyte infiltration, T lymphocyte subsets in peripheral blood,&#xD;
      granulocyte to lymphocyte ratio, tumor mutant burden (TMB), circulating tumor DNA (ctDNA),&#xD;
      exosomes，etc.，will be measured and monitored during the treatment. In addition，the safety&#xD;
      evaluation will be carried out according to the standard of adverse reaction classification&#xD;
      (Common Terminology Criteria for Adverse Events, CTCAE v5.0)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>9-month progression-free survival (PFS) rate (in subjects receiving TKI followed by TKI in combination with anti-PD-1 antibody)</measure>
    <time_frame>9 months</time_frame>
    <description>From the date of first dose of treatment to the first of either disease progression, relapse or death from any cause, evaluate patient PFS rate at 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the proportion of patients whose best overall response (BOR) is complete response (CR) or partial response (PR) assessed by iRECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from CR or PR to disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the proportion of patients whose BOR is CR, PR, and stable disease (SD) assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from the date of the first dose of treatment to the date of the first documentation of disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from the date of the first dose of treatment until the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>2 years</time_frame>
    <description>The grade of toxicity will be assessed using the NCI-CTCAE version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQOL)</measure>
    <time_frame>2 years</time_frame>
    <description>Score according to quality of life scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of biomarkers</measure>
    <time_frame>2 years</time_frame>
    <description>PD-1/PD-L1 expression, tumor-infiltrating lymphocytes, T lymphocyte subsets from peripheral blood samples, granulocyte-to-lymphocyte ratio, TMB, ctDNA, exosomes, dynamic changes in serum levels of protein tumor markers, etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>MSS</condition>
  <condition>pMMR</condition>
  <condition>Metastatic Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>TKI ± anti-PD-1 antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>According to response to TKI, the combination of anti-PD-1 treatment would be determined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI ± anti-PD-1 antibody</intervention_name>
    <description>After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.&#xD;
Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)&#xD;
Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years.</description>
    <arm_group_label>TKI ± anti-PD-1 antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who voluntarily participated in the study, signed the written informed&#xD;
             consent form, and could comply with the protocol of study.&#xD;
&#xD;
          -  Male or female of age 18-75 years.&#xD;
&#xD;
          -  Subjects with colorectal adenocarcinoma who were histopathologically confirmed, and&#xD;
             with locally advanced (unresectable) or mCRC.&#xD;
&#xD;
          -  Subjects who underwent standard antitumor therapies (fluorouracil, oxaliplatin,&#xD;
             irinotecan were used, with or without administration of bevacizumab and/or cetuximab).&#xD;
&#xD;
          -  Patients with MSS/pMMR mCRC (immunohistochemistry, polymerase chain reaction or&#xD;
             next-generation sequencing can be used).&#xD;
&#xD;
          -  All adverse reactions associated with drug use or surgery were reduced to grade 0-1&#xD;
             (according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0) or&#xD;
             to a level required by the protocol criteria.&#xD;
&#xD;
          -  The presence of at least one measurable lesion by computed tomography (CT) or magnetic&#xD;
             resonance imaging (MRI).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1.&#xD;
&#xD;
          -  Subjects with life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  Adequate important organs functions: bone marrow function (neutrophil count ≥&#xD;
             1.5×10^9/L; platelet ≥ 80×10^9/L; hemoglobin ≥ 90 g/L), liver function (serum albumin&#xD;
             ≥ 28 g/L; total bilirubin ≤ 1.5×upper limit of normal (ULN); alanine aminotransferase&#xD;
             and aspartate aminotransferase ≤ 3×ULN, or ≤ 5×ULN if liver metastases are present),&#xD;
             renal function (serum creatinine ≤ 1.5×ULN or creatinine clearance (CrCl) ≥ 40 mL/min,&#xD;
             using the Cockcroft-Gault formula; urine protein &lt; 2+; 24h urinary protein content &lt;&#xD;
             1.0 g/24h if urinary protein ≥ 2+ ), coagulation function (international normalized&#xD;
             ratio or activated partial thromboplastin time ≤ 2×ULN), thyroid function (thyrotropin&#xD;
             ≤ 1×ULN).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known microsatellite instability high (MSI-H) mCRC.&#xD;
&#xD;
          -  Participation in another study with intervention or drugs within the past 4 weeks.&#xD;
&#xD;
          -  Performing surgery and incomplete recovery within the past 4 weeks.&#xD;
&#xD;
          -  Subjects with active autoimmune diseases or with related history. Subjects with&#xD;
             controlled type I diabetes or hypothyroidism with substitution therapy may be included&#xD;
             for further screening.&#xD;
&#xD;
          -  Any conditions requiring corticosteroids (&gt; 10 mg per day of prednisone or equivalent)&#xD;
             or immunosuppressive drugs as systemic treatment within the past 1 week.&#xD;
&#xD;
          -  Other active malignancy within the past 5 years, except for the cured limited cancer&#xD;
             (such as basal cell carcinoma, carcinoma in situ of the prostate or cervix, etc.).&#xD;
&#xD;
          -  Subjects with history of hepatic encephalopathy or confirmed metastases to central&#xD;
             nervous system.&#xD;
&#xD;
          -  Subjects with non-infectious pneumonia under steroid treatment within the past 6&#xD;
             months.&#xD;
&#xD;
          -  Suffering from chronic or active infections, fever (≥ 38.5℃) within the past 1 week,&#xD;
             or white blood cell count &gt; 15×10^9/L), requiring systemic anti-infective treatment at&#xD;
             the screening period, except for viral hepatitis.&#xD;
&#xD;
          -  Subjects with any other abnormal condition that is inconsistent with the study&#xD;
             medication, or may increase the risk of the subject，according to investigators'&#xD;
             judgment.&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency (such as human immunodeficiency virus).&#xD;
&#xD;
          -  Subjects with active hepatitis B virus (HBV) (HBV surface antigen positive and HBV-DNA&#xD;
             &gt; 2000 IU/ml) or hepatitis C virus (HCV) (HCV antibody and HCV-RNA positive).&#xD;
&#xD;
          -  Subject who received a live attenuated vaccine within the past 4 weeks, or vaccination&#xD;
             is planned during anti-PD-1 antibody treatment or within 5 months after the last&#xD;
             treatment.&#xD;
&#xD;
          -  More than mild pericardial effusion, massive pleural or/and peritoneal effusions need&#xD;
             puncture and drainage at the screening period.&#xD;
&#xD;
          -  Subjects with symptomatic heart and cerebrovascular diseases: heart failure (New York&#xD;
             Heart Association class III or IV, left ventricular ejection fraction &lt; 50%),&#xD;
             uncontrolled hypertension or arrhythmias, serious cardiovascular and cerebrovascular&#xD;
             events (acute coronary syndrome, stroke, thromboembolism, etc.) within the past 6&#xD;
             months.&#xD;
&#xD;
          -  Known allergy to targeted drugs.&#xD;
&#xD;
          -  Women being pregnant, or during lactation, or planning to get pregnant during the&#xD;
             trial.&#xD;
&#xD;
          -  Subjects with any other conditions judged by investigators would be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingdong Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University, Liaoning Cancer Hospital &amp; Institute,China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qian Dong</last_name>
    <phone>17309815028</phone>
    <email>dongqian08@163.comcom</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital of China Medical University/Liaoning Cancer Hospital &amp;Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Dong, Doctor</last_name>
      <phone>17309815028</phone>
      <email>dongqian08@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Jingdong Zhang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>tyrosine kinase inhibitors (TKIs)</keyword>
  <keyword>programmed cell death protein 1 (PD-1)</keyword>
  <keyword>microsatellite stable/proficient mismatch repair (MSS/pMMR)</keyword>
  <keyword>metastatic colorectal adenocarcinoma (mCRC)</keyword>
  <keyword>trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The individual participant data will be available (including data dictionaries). All the individual participant data collected during the trial, after deidentification. All the study protocol, statistical analysis plan, informed consent form, clinical study report and analytic code will be available. The data will be available immediately following publication and no end date. The data will be shared with the researchers who provide a methodologically sound proposal to achieve aims in the approved proposal. The proposals should be directed to jdzhang@cancerhosp-ln-cmu.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Immediately following publication.No end date.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal. The proposals should be directed to jdzhang@cancerhosp-ln-cmu.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04483219
org study id: TRAP
nct id: NCT04483219
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The purpose of this study is to evaluate the efficacy and safety of fruquintinib or
      regorafenib in combination with anti-PD-1 antibody in TKI (fruquintinib or
      regorafenib)-responded MSS/pMMR metastatic colorectal adenocarcinoma.
At present, the later-line treatment of metastatic colorectal cancer (mCRC) can bring
      benefits to subjects. However, the overall efficacy of treatment is still low. The programmed
      cell death protein 1 (PD-1) blockade alone in MSS/pMMR mCRC is inefficiency, highlighting a
      need for strategies that converse the immunity suppressive to immunity supportive
      microenvironment. Fruquintinib and regorafenib are multi-target TKI mainly for angiogenesis,
      which has the following characteristics: cause tumor necrosis and release a lot of new
      antigens, improve the microenvironment of immunosuppression, and induce tumor vascular
      normalization. In addition to killing tumor cells, fruquintinib and regorafenib could also
      converse the immunity suppressive to immunity supportive microenvironment, which could
      sensitize PD-1 blockade, ultimately improve the prognosis of patients with MSS/pMMR mCRC.

      This prospective study is a single-arm, multicenter phase II clinical study to evaluate the
      efficacy and safety of fruquintinib or regorafenib in combination with anti-PD-1 antibody in
      TKI (fruquintinib or regorafenib)-responded MSS/pMMR metastatic colorectal cancer.

      In this prospective study, the 9-month PFS rate in subjects receiving TKI followed by TKI in
      combination with anti-PD-1 antibody, will be used as primary outcome measures and 53 subjects
      will be recruited.

      After fully informed and signed the informed consent, the subjects will receive one cycle of
      TKI (fruquintinib or regorafenib) treatment after enrollment. According to response to TKI,
      the subjects will be divided into three arms. The definition of response to TKI are as
      follows: (1) obvious response to TKI (arm A)：effective imaging changes, including reduction
      of target lesion diameter to CR, PR or shrunken SD (based on response evaluation criteria in
      solid tumors, RECIST v 1.1), or cavitation in metastatic lung lesions, or decrease in the
      density of liver metastatic target lesions ≥15%; (2) general response to TKI (arm B):
      enlarged SD (based on RECIST v 1.1); (3) poor response to TKI (arm C): PD (based on RECIST v
      1.1). TKI in combination with anti-PD-1 antibody will be administered in arm A. The subjects
      in arm C will exit the study. The subjects in arm B will continue to take TKI for another one
      cycle. After that, the obvious response subjects will be entered group A, the general
      response subjects will keep in arm B and continue the TKI monotherapy, and the poor response
      subjects will exit the study. The administration of arm A or B will be last until disease
      progression or intolerable toxicity，anti-PD-1 antibody can be applied for up to 2 years.

      The first two imaging evaluations would be performed every 4 weeks after the beginning of
      treatment to evaluate TKI response, and then once every 6 weeks, until the end of treatment,
      withdrawal of informed consent or death. The TKI response would be assessed according to
      RECIST v1.1 criteria and effective imaging changes (cavitation in metastatic lung lesions, or
      decrease in the density of liver metastatic target lesions ≥15%). The efficacy of TKI
      followed by TKI in combination with anti-PD-1 antibody would be evaluated based on
      immune-related RECIST (iRECIST) v1.1 criteria.

      PD-1/PD-L1 expression, T lymphocyte infiltration, T lymphocyte subsets in peripheral blood,
      granulocyte to lymphocyte ratio, tumor mutant burden (TMB), circulating tumor DNA (ctDNA),
      exosomes，etc.，will be measured and monitored during the treatment. In addition，the safety
      evaluation will be carried out according to the standard of adverse reaction classification
      (Common Terminology Criteria for Adverse Events, CTCAE v5.0)
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: 9-month progression-free survival (PFS) rate (in subjects receiving TKI followed by TKI in combination with anti-PD-1 antibody)
time frame: 9 months
description: From the date of first dose of treatment to the first of either disease progression, relapse or death from any cause, evaluate patient PFS rate at 9 months
measure: Objective response rate (ORR)
time frame: 2 years
description: Defined as the proportion of patients whose best overall response (BOR) is complete response (CR) or partial response (PR) assessed by iRECIST v1.1
measure: Duration of response (DOR)
time frame: 2 years
description: Defined as the time from CR or PR to disease progression or death.
measure: Disease control rate (DCR)
time frame: 2 years
description: Defined as the proportion of patients whose BOR is CR, PR, and stable disease (SD) assessed.
measure: Progression-free survival (PFS)
time frame: 2 years
description: Defined as the time from the date of the first dose of treatment to the date of the first documentation of disease progression or death, whichever occurs first.
measure: Overall survival (OS)
time frame: 2 years
description: Defined as the time from the date of the first dose of treatment until the date of death due to any cause.
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
time frame: 2 years
description: The grade of toxicity will be assessed using the NCI-CTCAE version 5.0.
measure: Health-related quality of life (HRQOL)
time frame: 2 years
description: Score according to quality of life scale.
measure: Exploration of biomarkers
time frame: 2 years
description: PD-1/PD-L1 expression, tumor-infiltrating lymphocytes, T lymphocyte subsets from peripheral blood samples, granulocyte-to-lymphocyte ratio, TMB, ctDNA, exosomes, dynamic changes in serum levels of protein tumor markers, etc.
arm group label: TKI ± anti-PD-1 antibody
arm group type: Experimental
description: According to response to TKI, the combination of anti-PD-1 treatment would be determined.
intervention type: Drug
intervention name: TKI ± anti-PD-1 antibody
description: After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.
Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)
Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years.
arm group label: TKI ± anti-PD-1 antibody
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Jingdong Zhang
role: Principal Investigator
affiliation: China Medical University, Liaoning Cancer Hospital & Institute,China
last name: Qian Dong
phone: 17309815028
email: dongqian08@163.comcom
facility: 
status: Recruiting
contact: 
country: China
responsible party type: Principal Investigator
investigator affiliation: China Medical University, China
investigator full name: Jingdong Zhang
investigator title: Director
mesh term: Adenocarcinoma
mesh term: Antibodies
sharing ipd: Yes
ipd description: The individual participant data will be available (including data dictionaries). All the individual participant data collected during the trial, after deidentification. All the study protocol, statistical analysis plan, informed consent form, clinical study report and analytic code will be available. The data will be available immediately following publication and no end date. The data will be shared with the researchers who provide a methodologically sound proposal to achieve aims in the approved proposal. The proposals should be directed to jdzhang@cancerhosp-ln-cmu.com.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd info type: Clinical Study Report (CSR)
ipd info type: Analytic Code
ipd time frame: Immediately following publication.No end date.
ipd access criteria: Researchers who provide a methodologically sound proposal. The proposals should be directed to jdzhang@cancerhosp-ln-cmu.com.